02 November 2020
: Case report 
Successful Clozapine Re-Challenge After Suspected Clozapine-Induced Myocarditis
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy
Seyed Alireza Hosseini1BCDEF*, Brianna Skrzypcak1BEF, Rama Yasaei1ABD, Sara Abdijadid1ADE, Fowrooz Joolhar2DE, Theingi Tiffany Win2E, Leila Moosavi3ADDOI: 10.12659/AJCR.926507
Am J Case Rep 2020; 21:e926507
Table 1. Results of laboratory testing after chest pain onset (day 16 of clozapine therapy).
| Variable (unites) | Patient’s value | Normal range |
|---|---|---|
| C-reactive protein (mg/dL) | 20.8 | 0–0.3 |
| Erythrocyte sedimentation rate (mm/h) | >100 | 0–15 |
| Troponin I (µg/L) | 0.72 | 0.00–0.05 |
| B-type natriuretic peptide (ng/mL) | 999 | 0–38 |
| Leukocyte count (×10/L) | 11.4 | 4.0–11.0 |
| Eosinophil count (×10/L) | 1.1 | 0–0.7 |
| Creatine Kinase (U/L) | 272 | 27–283 |
| Hemoglobin (g/dL) | 10.8 | 13.0–17.3 |
| Red blood cell count (×10/L) | 3.57 | 4.3–5.8 |
| D-Dimer (ng/mL) | 2018 | 0–500 |
| Hepatitis A IgM antibody | Reactive | Non-reactive |
| * Abnormal value. | ||